Table 1. Characteristics of studies included in the meta-analysis.
| MDS Subtype |
MDS | IPSS | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | Country | n/N | Age(years) | Sex(M/F) | RA/RCUD /RARS |
RAEB/ RAEB-t |
RCMD/ RCMD-RS |
CMML | Others | criteria | Low+Int1/Int2+ High/Unknown |
Adjustments | NOS |
| Wu | China | 13/304 | 57(11,89)* | 162/142 | 0/20/9 | 123/0 | 0/145 | 0 | 7 | WHO | 212/90/2 | 1,2,5,6,7 | 9 |
| 2016 | |||||||||||||
| Cui | China | 42/145 | 63(18,85)* | 98/47 | 0/0/0 | 0/0 | 0/0 | 145 | 0 | WHO | NR | NR | 8 |
| 2015 | |||||||||||||
| Kim | Korea | 5/52 | 52(18,73)* | 36/16 | 2/0/1 | 27/0 | 20/0 | 0 | 2 | WHO | 22/30/0 | 6,7 | 7 |
| 2015 | |||||||||||||
| Kang | Korea | 13/129 | 63.7±12.4# | 71/58 | 0/19/0 | 46/0 | 56/0 | 0 | 8 | WHO | NR | 1,2,4,7 | 8 |
| 2015 | |||||||||||||
| Karimi | Sweden | 15/100 | 72(32,88)* | 51/49 | 0/0/10 | 41/0 | 2/11 | 15 | 21 | WHO | NR | 1,2,4,7 | 8 |
| 2015 | |||||||||||||
| Lin | China | 5/108 | 60(20,86)* | 64/45 | 10/0/0 | 48/0 | 36/8 | 0 | 6 | WHO | 72/32/4 | 1,2,3,5,7 | 9 |
| 2014 | |||||||||||||
| Itzykson | France | 101/312 | 74(41,93)* | 210/102 | 0/0/0 | 0/0 | 0/0 | 312 | 0 | WHO | NR | 7 | 7 |
| 2013 | |||||||||||||
| Thol | Germany | 24/193 | NR(36,92)* | 119/74 | 38/0/20 | 53/0 | 21/9 | 0 | 52 | WHO | 96/51/43 | 1,3,7 | 8 |
| 2012 | |||||||||||||
| Wu | China | 34/233 | 66(18,95)* | 161/72 | 98 | 102 | 0/0 | 33 | 0 | FAB | 115/99/19 | 1,3,7 | 8 |
| 2012 | |||||||||||||
| Bejar | USA | 42/288 | 69(15,90)* | 203/85 | 173/0/41 | 71/3※ | 0/0 | 0 | 0 | FAB | 288/0/0 | 1,2,3,7 | 8 |
| 2012 |
Abbreviations: CMML, chronic myelomonocytic leukemia; FAB, French American British classification; IPSS, International Prognostic Scoring System; MDS, myelodysplastic syndromes; n, number of patients with SRSF2 mutations; N, number of patients in total; NOS, Newcastle-Ottawa quality assessment scale; NR, not reported; RA, refractory anemia; RARS, RA with ringed sideroblasts; RAEB, RA with excess blasts; RAEB-t, RAEB in transformation; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, refractory cytopenia with multilineage dysplasia and ringed sideroblasts; RCUD, refractory cytopenia with unilineage dysplasia; WHO, World Health Organization.
*, median age (range)
#, mean age ± SD
※, the 3 patients with RAEB-t had circulating blasts but≤10% blasts in the bone marrow.
Main adjusted variables in multivariate Cox proportional hazards models: 1 = age; 2 = sex; 3 = IPSS; 4 = IPSS-R; 5 = neutrophils; 6 = hemoglobin; 7 = mutation status